Physician profile
Angela Lower
NPI 1740405497
$2,682.68
in general payments reported to CMS, 2019-2025
32 companies · $916 in 2025
The $916 reported for 2025 was more than what 82% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $34.17 · 2022: $294 · 2023: $510 · 2024: $929 · 2025: $916.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,267 · Education: $87.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,266.62 |
| Education | $87.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $302.10 | 2022-2025 | Briviact, Fintepla, Nayzilam |
| Abbvie INC. | $270.24 | 2023-2025 | |
| Argenx US, INC. | $203.36 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Sk Life Science, INC. | $176.63 | 2022-2025 | |
| Amneal Pharmaceuticals LLC | $118.55 | 2023-2025 | Crexont, Rytary |
| Alexion Pharmaceuticals, INC. | $116.18 | 2023-2025 | Ultomiris, Soliris |
| Celgene Corporation | $112.95 | 2023-2024 | Zeposia |
| Biogen, INC. | $110.06 | 2023-2025 | Tysabri, Skyclarys |
| Emd Serono, INC. | $95.29 | 2024-2025 | |
| Acorda Therapeutics, INC | $93.49 | 2022-2023 | Inbrija |
| Novartis Pharmaceuticals Corporation | $89.45 | 2024-2025 | |
| Genentech USA, INC. | $88.24 | 2021-2024 | Enspryng, Ocrevus |
| Teva Pharmaceuticals USA, INC. | $87.49 | 2024 | |
| Eisai INC. | $85.45 | 2023-2025 | |
| Jazz Pharmaceuticals INC. | $73.38 | 2023-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cala Health, INC. | $72.92 | 2022-2025 | Cala Trio, Cala Kiq, Cala Kiq |
| Catalyst Pharmaceuticals, INC. | $69.11 | 2023-2025 | Fycompa |
| Pfizer INC. | $64.58 | 2023-2025 | |
| Avion Pharmaceuticals | $63.18 | 2021-2022 | |
| Neurelis, INC. | $58.51 | 2023-2025 | Valtoco |
| Boston Scientific Corporation | $47.70 | 2023-2024 | |
| Lilly USA, LLC | $46.19 | 2024-2025 | Kisunla, Emgality |
| Aucta Pharmaceuticals, INC. | $44.96 | 2025 | Motpoly Xr |
| Tanabe Pharma America, INC. | $28.12 | 2024 | |
| Merz Pharmaceuticals, LLC | $25.06 | 2025 | Xeomin, Inbrija |
| Xeris Pharmaceuticals, INC. | $24.81 | 2025 | Keveyis |
| Acadia Pharmaceuticals INC | $24.46 | 2025 | Daybue |
| Novo Nordisk INC | $24.23 | 2023 | |
| Itf Therapeutics LLC | $19.51 | 2025 | |
| Kyowa Kirin, INC. | $17.40 | 2024 | Nourianz |
| Astrazeneca Pharmaceuticals LP | $15.87 | 2024 | Wainua |
| Neurocrine Biosciences, INC. | $13.21 | 2024 | Ingrezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Lower listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.